Effects of the vanilloid agonist olvanil and antagonist capsazepine on rat behaviors

Kasckow, John; Mulchahey, J.J.; Geracioti, Thomas D.

doi:10.1016/j.pnpbp.2003.10.007

Cited by 78 publications

(56 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although the antidepressant-like effects of OL on the forced swimming behaviors are consistent with the data from a previous study [29], the antidepressant-like modifications of TRPV1 agonists against the effects of NC and IM have not been reported in representative behavioral tests. Furthermore, for these antidepressant-like effects, the involvement of TRPV1 receptors was demonstrated by their attenuation using the TRPV1 antagonist CZ (Figure 3 and 4), which has also been reported for the CP-induced hypolocomotor effects in the open-field test [33].…”

Section: Discussionsupporting

confidence: 85%

“…With respect to the doses of the TRPV1 ligands, the doses for the repeated administrations were selected based on previous studies and preliminary experiments [27,29,33-35]. For each drug, the data were collected and shown for those intraperitoneal (i.p.)…”

Section: Methodsmentioning

confidence: 99%

“…The data obtained were subjected to a two-way analysis of variance (ANOVA) for the factors NC or IM treatment × treatment using each TRPV1 ligand [29]. With respect to the experiments examining the role of TRPV1 and CB1 receptors, the data obtained were subjected to a three-way ANOVA for the factors NC or IM treatment × treatment using each effective TRPV1 ligand × treatment using the TRPV1 or CB1 antagonist [39].…”

Section: Methodsmentioning

confidence: 99%

“…There have been few studies on the contribution of TRPV1 receptors to NC-induced behavioral effects, although antidepressant actions have been demonstrated for TRPV1 agonists such as olvanil [29]. Furthermore, the existence of a number of "candidate" endogenous TRPV1 ligands, which are expected to provide therapeutic effects against pathological conditions such as behavioral disorders, has been reported [30,31].…”

Section: Introductionmentioning

confidence: 99%

“…In the present study, based on the involvement of TRPV1 receptors in the effects of CB1 ligands, the functional relationship between nAChRs and TRPV1 receptors [32], and the author's preliminary data on the antidepressant-like effects of some cannabimimetics against NC-induced depression-like behaviors [10], the effects of TRPV1 ligands with or without affinity for CB1 receptors were examined against NC- and IM-induced depression-like behaviors in mice. Since few references on the depression-related behavioral alterations caused by TRPV1 ligands are available, the TRPV1 ligands were selected from those which provided some behavioral effects upon intraperitoneal or intravenous injections: the prototypic agonist capsaicin (CP) [33], the potent and antidepressant agonist olvanil (OL) [29], the antagonist capsazepine (CZ) [29], the endogenous TRPV1-agonistic CB1 agonists anandamide (arachidonylethanolamide: AEA) [27] and N-arachidonyldopamine (NADA) [34], as well as the synthetic TRPV1 and CB1 agonist arvanil (AR) [35]. …”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Differential effects of TRPV1 receptor ligands against nicotine-induced depression-like behaviors

Hayase

2011

BMC Pharmacol

View full text Add to dashboard Cite

BackgroundThe contributions of brain cannabinoid (CB) receptors, typically CB1 (CB type 1) receptors, to the behavioral effects of nicotine (NC) have been reported to involve brain transient receptor potential vanilloid 1 (TRPV1) receptors, and the activation of candidate endogenous TRPV1 ligands is expected to be therapeutically effective. In the present study, the effects of TRPV1 ligands with or without affinity for CB1 receptors were examined on NC-induced depression-like behavioral alterations in a mouse model in order to elucidate the "antidepressant-like" contributions of TRPV1 receptors against the NC-induced "depression" observed in various types of tobacco abuse.ResultsRepeated subcutaneous NC treatments (NC group: 0.3 mg/kg, 4 days), like repeated immobilization stress (IM) (IM group: 10 min, 4 days), caused depression-like behavioral alterations in both the forced swimming (reduced swimming behaviors) and the tail suspension (increased immobility times) tests, at the 2 h time point after the last treatment. In both NC and IM groups, the TRPV1 agonists capsaicin (CP) and olvanil (OL) administered intraperitoneally provided significant antidepressant-like attenuation against these behavioral alterations, whereas the TRPV1 antagonist capsazepine (CZ) did not attenuate any depression-like behaviors. Furthermore, the endogenous TRPV1-agonistic CB1 agonists anandamide (AEA) and N-arachidonyldopamine (NADA) did not have any antidepressant-like effects. Nevertheless, a synthetic "hybrid" agonist of CB1 and TRPV1 receptors, arvanil (AR), caused significant antidepressant-like effects. The antidepressant-like effects of CP and OL were antagonized by the TRPV1 antagonist CZ. However, the antidepressant-like effects of AR were not antagonized by either CZ or the CB1 antagonist AM 251 (AM).ConclusionsThe antidepressant-like effects of TRPV1 agonists shown in the present study suggest a characteristic involvement of TRPV1 receptors in NC-induced depression-like behaviors, similar to those caused by IM. The strong antidepressant-like effects of the potent TRPV1 plus CB1 agonist AR, which has been reported to cause part of its TRPV1-mimetic and cannabimimetic effects presumably via non-TRPV1 or non-CB1 mechanisms support a contribution from other sites of action which may play a therapeutically important role in the treatment of NC abuse.

show abstract

Section: Discussionsupporting

confidence: 85%